Table 3. Univariate and multivariate Cox regression analyses for BCSS and OS in estrogen receptor-positive mucinous breast cancer.
| Variables | Univariate Cox regression | Multivariate Cox regression | ||||||
|---|---|---|---|---|---|---|---|---|
| Unadjusted HR | 95% CI | p-value | Adjusted HR | 95% CI | p-value | |||
| BCSS | ||||||||
| Age (yr) | ||||||||
| > 50/≤ 50 | 2.292 | 1.177–4.462 | 0.015 | 1.441 | 0.564–3.682 | 0.445 | ||
| Pathologic tumor stage | ||||||||
| T2, 3, 4/T1 | 1.857 | 0.936–3.687 | 0.077 | - | - | - | ||
| Pathologic nodal stage | ||||||||
| N1, 2, 3/N0 | 4.487 | 2.241–8.985 | < 0.001 | 5.358 | 2.175–13.200 | < 0.001 | ||
| Histologic grade | ||||||||
| Grade 3/Grade 1, 2 | 1.766 | 0.507–6.146 | 0.365 | - | - | - | ||
| LVI | ||||||||
| Yes/No | 2.101 | 0.892–4.946 | 0.089 | - | - | - | ||
| PR status | ||||||||
| Negative/Positive | 1.502 | 0.703–3.210 | 0.293 | - | - | - | ||
| p53 | ||||||||
| Positive/Negative | 0.028 | 0.001–1.452 | 0.076 | - | - | - | ||
| HER-2 status | ||||||||
| Positive/Negative | 1.213 | 0.283–5.208 | 0.795 | - | - | - | ||
| Radiotherapy | ||||||||
| No/Yes | 3.888 | 1.411–10.719 | 0.009 | 3.346 | 1.198–9.293 | 0.021 | ||
| Hormone therapy | ||||||||
| No/Yes | 0.745 | 0.100–5.550 | 0.774 | - | - | - | ||
| Chemotherapy | ||||||||
| No/Yes | 0.208 | 0.061–0.709 | 0.012 | 0.393 | 0.106–1.453 | 0.162 | ||
| OS | ||||||||
| Age (yr) | ||||||||
| > 50/≤ 50 | 3.134 | 2.186–4.492 | < 0.001 | 3.200 | 1.867–5.488 | < 0.001 | ||
| Pathologic tumor stage | ||||||||
| T2, 3, 4/T1 | 2.088 | 1.444–3.020 | < 0.001 | 1.962 | 1.116–3.449 | 0.019 | ||
| Pathologic nodal stage | ||||||||
| N1, 2, 3/N0 | 2.949 | 2.025–4.294 | < 0.001 | 2.876 | 1.665–4.967 | < 0.001 | ||
| Histologic grade | ||||||||
| Grade 3/Grade 1, 2 | 0.849 | 0.390–1.852 | 0.682 | - | - | - | ||
| LVI | ||||||||
| Yes/No | 1.677 | 1.085–2.593 | 0.020 | 1.406 | 0.797–2.480 | 0.240 | ||
| PR status | ||||||||
| Negative/Positive | 1.294 | 0.858–1.954 | 0.219 | - | - | - | ||
| p53 | ||||||||
| Positive/Negative | 0.989 | 0.619–1.578 | 0.962 | - | - | - | ||
| HER-2 status | ||||||||
| Positive/Negative | 1.863 | 1.010–3.439 | 0.046 | 1.495 | 0.698–3.199 | 0.300 | ||
| Radiotherapy | ||||||||
| No/Yes | 2.381 | 1.572–3.606 | < 0.001 | 1.252 | 0.735–2.317 | 0.408 | ||
| Hormone therapy | ||||||||
| No/Yes | 0.890 | 0.389–2.034 | 0.782 | - | - | - | ||
| Chemotherapy | ||||||||
| No/Yes | 0.818 | 0.549–1.220 | 0.326 | - | - | - | ||
BCSS = breast cancer-specific survival; OS = overall survival; HR = hazard ratio; CI = confidence interval; LVI = lymphovascular invasion; PR = progesterone receptor; HER-2 = human epidermal growth factor receptor 2.